Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies, including Hims & Hers and other compounding pharmacies, as similar alternatives to FDA-approved drugs. The agency said the actions are intended to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. The agency also emphasized ongoing concerns around promotional claims and direct-to-consumer messaging, building on the The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025, the agency said
& Alhejeli, A
While the occasional drink or two may not bother you, you may want to wait until youve got a handle on any side effects before you toast your success with a celebratory glass of wine
women should discuss existing NICE-approved options such as semaglutide (Wegovy) or tirzepatide (Mounjaro) with their GP
241 GLP-1R is expressed not only on -cells and -cells but also on -cells in the pancreatic islets
The most common formula, known as MIC B12, combines methionine, inositol, choline, and vitamin B12, all of which play specific roles in fat metabolism, liver function, and energy production